Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Exact Sciences Corp (EXAS)  
$61.41 1.94 (3.06%) as of 4:30 Tue 5/7


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 177,680,000
Market Cap: 10.91(B)
Last Volume: 1,933,966 Avg Vol: 1,913,064
52 Week Range: $56.27 - $99.04
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:
    NASDAQ COMPOSITE     NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  568
Guru Rank Value     : 3
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   Exact Sciences is a cancer screening and diagnostics company. Co.'s primary screening product, the Cologuard® test, is a non-invasive stool-based DNA screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. Co.'s portfolio of Oncotype tests include: Oncotype DX gene expression tests for breast, prostate and colon cancers; Oncotype DX AR-V7 Nucleus Detect® test, a liquid-based test for advanced stage prostate cancer; and Oncotype MAP™ Pan-Cancer Tissue test (oncomap test), a test delivering tumor profiling to aid therapy selection for patients with metastatic, refractory or recurrent cancer.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 103,519 108,398 180,881 290,334
Total Sell Value $6,219,303 $6,570,910 $12,429,896 $18,676,003
Total People Sold 10 10 11 11
Total Sell Transactions 49 52 65 100
End Date 2024-02-08 2023-11-07 2023-05-09 2022-05-09

   
Records found: 957
  Page 3 of 39  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Conroy Kevin T President and CEO   •       •      –    2024-02-23 4 OE $13.96 $1,435,605 D/D 102,837 1,344,266     -
   Condella Sarah EVP, Human Resources   •       –      –    2024-02-23 4 AS $59.72 $60,974 D/D (1,021) 71,658 8%     
   Cunningham Everett Chief Commercial Officer   •       –      –    2024-02-22 4 AS $59.78 $80,703 D/D (1,350) 39,270 4%     
   Conroy Kevin T President and CEO   •       •      –    2024-02-22 4 AS $59.78 $691,356 D/D (11,565) 1,241,429 4%     
   Elliott Jeffrey Thomas Chief Financial Officer   •       –      –    2024-02-22 4 AS $59.78 $80,763 D/D (1,351) 5,063 4%     
   Orville Jacob A General Manager, Screening   •       –      –    2024-02-22 4 AS $59.78 $60,557 D/D (1,013) 9,679 4%     
   Baranick Brian Gen. Mgr., Precision Oncology   •       –      –    2024-02-22 4 AS $59.78 $65,340 D/D (1,093) 9,767 4%     
   Coward D Scott Director   –       •      –    2024-02-22 4 AS $59.78 $39,634 D/D (663) 44,493 4%     
   Herriott James General Counsel   •       –      –    2024-02-22 4 AS $59.78 $17,396 D/D (291) 7,233 4%     
   Condella Sarah EVP, Human Resources   •       –      –    2024-02-22 4 AS $59.78 $60,557 D/D (1,013) 72,679 4%     
   Cunningham Everett Chief Commercial Officer   •       –      –    2024-02-21 4 A $0.00 $0 D/D 2,711 40,620     -
   Conroy Kevin T President and CEO   •       •      –    2024-02-21 4 A $0.00 $0 D/D 23,238 1,252,994     -
   Elliott Jeffrey Thomas Chief Financial Officer   •       –      –    2024-02-21 4 A $0.00 $0 D/D 2,711 6,414     -
   Orville Jacob A General Manager, Screening   •       –      –    2024-02-21 4 A $0.00 $0 D/D 2,034 10,692     -
   Baranick Brian Gen. Mgr., Precision Oncology   •       –      –    2024-02-21 4 A $0.00 $0 D/D 2,034 10,860     -
   Coward D Scott Director   –       •      –    2024-02-21 4 A $0.00 $0 D/D 2,034 45,156     -
   Herriott James General Counsel   •       –      –    2024-02-21 4 A $0.00 $0 D/D 581 7,524     -
   Condella Sarah EVP, Human Resources   •       –      –    2024-02-21 4 A $0.00 $0 D/D 2,034 73,692     -
   Condella Sarah EVP, Human Resources   •       –      –    2024-02-21 4 AS $61.50 $66,359 D/D (1,079) 71,658 -2%     
   Conroy Kevin T President and CEO   •       •      –    2024-02-21 4 AS $61.50 $305,963 D/D (4,975) 1,229,756 -2%     
   Baranick Brian Gen. Mgr., Precision Oncology   •       –      –    2024-02-21 4 AS $61.50 $55,043 D/D (895) 8,826 -2%     
   Coward D Scott Director   –       •      –    2024-02-21 4 AS $61.50 $43,419 D/D (706) 43,122 -2%     
   Elliott Jeffrey Thomas Chief Financial Officer   •       –      –    2024-02-21 4 AS $61.50 $91,820 D/D (1,493) 3,703 -2%     
   Orville Jacob A General Manager, Screening   •       –      –    2024-02-21 4 AS $61.50 $66,297 D/D (1,078) 8,658 -2%     
   Herriott James General Counsel   •       –      –    2024-02-21 4 AS $61.50 $25,523 D/D (415) 6,943 -2%     
  957 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 3 of 39
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us